177Lu-BRP-020063 / BoomRay Pharmaceuticals - LARVOL DELTA

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Urothelial Cancer

Preclinical evaluation of BRP-020063, a first-in-class peptide based radiopharmaceutical for the treatment of nectin4-positive cancers (AACR 2026) - "The preclinical in vitro and in vivo data demonstrate that 177Lu[Lu]-BRP-020063 possesses excellent target specificity, favorable pharmacokinetic properties, and potent antitumor efficacy. These findings strongly support further investigation of the novel therapeutic 177Lu[Lu]-BRP-020063 as a treatment for patients with Nectin4-positive solid tumors."

Preclinical • Bladder Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NECTIN1 • NECTIN4

A Clinical Study on the Safety, Pharmacokinetics, and Radiation Dosimetry of ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 Injection in Patients with Advanced Metastatic Solid Tumors. (ChiCTR) - P=N/A | N=10 | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New trial • Breast Cancer • Oncology • Solid Tumor

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

New P1 trial • Breast Cancer • Oncology • Solid Tumor • Urothelial Cancer